Table 3.
PI3K alterations in trastuzumab refractory lesions versus untreated HER2+ cohort
PIK3CA mutation or PTEN absent/reduced expression | P value | ||
---|---|---|---|
Trastuzumab refractory cohort | Primary untreated HER2+ cohort | ||
PIK3CA | 13/45 (29%, 95%CI 16–44%) | 13/73 (18%, 95%CI 10–29%) | .176 |
PTEN | 33/56 (59%, 95% CI 46–71%) | 25/73 (34%, 95% CI 24–46%) | .007 |
PIK3CA or PTEN | 29/41 (71%, 95% CI 54–83%) | 32/73 (44%, 95% CI 32–56%) | .007 |